DelveInsight’s “Metastatic Triple Negative Breast Cancer (mTNBC)” report delivers an in-depth understanding of the Metastatic Triple Negative Breast Cancer (mTNBC), historical and forecasted epidemiology as well as the Metastatic Triple Negative Breast Cancer market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Get Sample Copy of Metastatic Triple Negative Breast Cancer Market
Key Highlights from the Metastatic Triple Negative Breast Cancer Market Report:
Metastatic Triple Negative Breast Cancer (mTNBC) market report provides current treatment practices, emerging drugs, Metastatic Triple Negative Breast Cancer (mTNBC) market share of the individual therapies, current and forecasted Hypertrophic Cardiomyopathy market Size from 2018 to 2030 segmented by seven major markets.
The Report also lays forward current mTNBC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Metastatic Triple Negative Breast Cancer: Disease Overview
Metastatic Triple Negative Breast Cancer is characterized as a metastatic tumor in which the estrogen and progesterone (ER/PR) receptors are negative by immunohistochemistry (IHC) and
there is no overexpression of HER2 by immunohistochemistry (IHC) or no gene amplification by fluorescence in situ hybridization technique. TNBC (ER-PR-HER2-) and other breast cancers have different epidemiological risk factor profiles.
According to breastcancer.org, about 70% of breast cancers diagnosed in people who have an inherited BRCA mutation, particularly BRCA1, are triple-negative.
TNBCs are slightly larger and of higher grade than non-TNBCs, according to secondary sources, but they are less likely to have lymph node metastases.
Metastatic Triple Negative Breast Cancer Epidemiology Segmentation
DelveInsight’s Metastatic Triple Negative Breast Cancer Market Report proffers historical as well as forecasted insights into the epidemiology of the indication for the study period 2018-30 in the 7MM segmented into:
Request for Sample Pages: Metastatic Triple Negative Breast Cancer Market Insight
Metastatic Triple Negative Breast Cancer Treatment Landscape
Currently, the treatment paradigm for mTNBC includes few treatment options such as systemic chemotherapies, neoadjuvant or adjuvant chemotherapy, surgery and radiation.
Few US FDA approved drugs, such as:
Various off label drugs are used for treating mTNBC which include:
Metastatic Triple Negative Breast Cancer Market
Metastatic Triple Negative Breast Cancer Market is expected to witness the launch of upcoming therapies by key pharmaceutical companies including Hoffman-La Roche, Infinity Pharmaceuticals, Cytodyn, and several others. The launch of Ipatasertib (Hoffman-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (Cytodyn), etc. is anticipated to provide a major push to the growth of the mTNBC market size in the forecast period 2018-30 in the 7MM.
Learn more about market insights @ mTNBC Market Analysis, and Forecast
Metastatic Triple Negative Breast Cancer Emerging Drugs
Metastatic Triple Negative Breast Cancer Market Drivers
Metastatic Triple Negative Breast Cancer Market Barriers
To learn more, visit Metastatic Triple Negative Breast Cancer Market Insights and Forecasted Trends
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)
Study Period: 2018-30
Key Companies in mTNBC Market: Hoffmann-La Roche, Infinity Pharmaceuticals, HiberCell, CytoDyn, Treadwell Therapeutics, and several others.
Key mTNBC Pipeline therapies: Ipatasertib (RG7440), IPI-549 (Eganelisib), Pembrolizumab (Imprime PGG), Leronlimab (PRO 140), CFI-400945 and several others.
mTNBC Market Segmentation: By Geography, By mTNBC therapies
Analysis: Comparative and conjoint analysis of mTNBC emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Get in touch with our Business executive for Pharma and Healthcare Market Assessment and Consulting
Table of Contents
1. | Key Insights |
2. | Triple Negative Breast Cancer Market Overview at a Glance |
3. | Disease Background and Overview: Triple Negative Breast Cancer |
4. | Unmet Needs |
5. | Epidemiology and Patient Population |
6. | Country Wise-Epidemiology of TNBC |
7. | Treatment Practices |
8. | Marketed Drug Analysis |
9. | Emerging Therapies |
10. | Metastatic Triple Negative Breast Cancer (mTNBC): 7MM Market Analysis |
11. | Market Outlook by Country |
12. | Market Drivers |
13. | Market Barriers |
14. | Appendix |
15. | DelveInsight Capabilities |
16. | Disclaimer |
17. | About DelveInsight |
Related Reports
DelveInsight’s “Metastatic Bone Pain – Market Insights, Epidemiology, and Market Forecast-2030” report.
Metastatic Castration Resistant Prostate Cancer Market
DelveInsight’s “Metastatic Castration Resistant Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030” report.
Metastatic Castration-Sensitive Prostate Cancer Market
DelveInsight’s “Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Market Insights, Epidemiology, and Market Forecast-2030” report.
Metastatic Colorectal Cancer Market
Get comprehensive historical and forecast analysis of Metastatic Colorectal Cancer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Merck, Eli Lilly, Bristol-Myers Squibb, Amgen, Taiho Oncology, Pfizer, Isofol Medical, Ab Science, Effector Therapeutics, Vaximm, Cardiff Oncology, others.
Metastatic Cutaneous Squamous Cell Cancer Market
DelveInsight’s “Metastatic Cutaneous Squamous Cell Cancer – Market Insights, Epidemiology, and Market Forecast-2030” report.
Metastatic Hepatocellular Carcinoma Market
DelveInsight’s “Metastatic Hepatocellular Carcinoma – Market Insights, Epidemiology, and Market Forecast-2030” report.
Metastatic HER2 Positive Breast Cancer Market
DelveInsight’s “Metastatic HER2 Positive Breast Cancer – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s “Metastatic Melanoma – Market Insights, Epidemiology, and Market Forecast-2030” report.
Metastatic Merkel Cell Carcinoma Market
DelveInsight’s “Metastatic Merkel Cell Carcinoma- Market Insights, Epidemiology, and Market Forecast-2030″ report.
Metastatic Prostate Cancer Market
DelveInsight’s “Metastatic Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030” report.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Visit for more insights into Pharma, Healthcare and Biotech News
Connect With Us at: